sb 203580 has been researched along with Neoplasms, Nervous System in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Canepa, E; Colla, R; De Ciucis, CG; Domenicotti, C; Furfaro, AL; Marengo, B; Marinari, UM; Pronzato, MA; Ricciarelli, R; Traverso, N | 1 |
1 other study(ies) available for sb 203580 and Neoplasms, Nervous System
Article | Year |
---|---|
p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Neoplasm Proteins; Neoplasm Staging; Nervous System Neoplasms; Neuroblastoma; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction | 2013 |